Figure 3.

Distribution, tissue-specific pharmacokinetics and cumulated activity of lutetium‑177- and copper‑67-labeled TATE variants in MPC allograft mice measured by quantitative SPECT imaging; animals received 50 MBq of the radioligands each prepared at different molar activities corresponding to molar amounts of 1.25 nmol (A_m = 40 MBq/nmol) and 2.5 nmol (A_m = 20 MBq/nmol) at treatment start; (A) Maximum-intensity projections of SPECT images at indicated time points and scaling; image series from treatments with radioligands at a molar activity of 40 MBq/nmol; (B-C) Time-courses of tissue-specific activity concentration after treatment; (D) Tissue-specific mean cumulated volume activity calculated from areas under curves; (E) Time-courses of excreted activity; data presented without decay correction as means ± standard error; significance of differences: * p < 0.05 ** p < 0.01, *** p < 0.001.